Trevena (TRVN) seeks to submit its opioid painkiller oliceridine for FDA marketing approval in the fourth quarter. Oliceridine intends to provide post-surgery intravenous pain relief comparable with standard morphine, while reducing common side effects that include nausea, vomiting and depressed breathing. Although these side effects are known for increasing hospital stays and costs, if approved, the pain killer will be significantly more expensive than morphine. Will hospitals be able to justify the cost?
READ THE FULL STORY HERE